肿瘤成像临床研究表明CTR-FAPI有潜力成为下一代更高灵敏度的FAPI-PET探针。由于可连接SuFEx弹头的蛋白质较为广泛，这一策略或可用于靶向其他靶点的放射性药物，并为调控其他低分子量偶联类药物的药代动力学提供了新途径。

EQS-News: Eckert & Ziegler SE / Key word (s): Contract/Alliance Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply 08.10.2024 / 08:00 CET/CEST The issuer is solely responsible ...

Detailed price information for Monopar Therapeutics Inc (MNPR-Q) from The Globe and Mail including charting and trades.

Germany’s Eckert & Ziegler has signed a global clinical supply agreement with Australian firm GlyTherix, providing GMP-grade ...

"Tumor behavior upon recurrence is often more aggressive, and patients may quickly exhaust safe and effective options for ...

智通财经APP获悉，放射性配体疗法(RLT疗法)这一市场预计到2030年将实现大幅增长，而诺华制药(NVS.US)旗下RLT产品Pluvicto有望在前列腺癌疗法领域占据最大份额。在全球超一半国家中，前列腺癌被定为男性中最常被确诊的癌症。前列腺癌的发 ...

Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced ...

Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User ...

The University of Missouri Research Reactor (MURR) has successfully delivered its first batch of no-carrier-added lutetium-177 (NCA Lu-177) for cancer treatment. The weekly shipments are being ...

"前列腺癌新药的上市将引领放射性药品市场。" 25日,在首尔永登浦区康拉德酒店举行的记者招待会上,Cellbion代表金权(音)提出了在KOSDAQ上市的蓝图。

A radionuclide agent, Lu-177 dotatate was approved by the FDA in 2018 for gastroenteropancreatic neuroendocrine tumors ...

VALENCIA, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of two executives to support its ...